References
- Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223–235.
- Coiffier B, Lepage E, Brière J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Wrench D, Montoto S. Chemotherapy: maintenance rituxi-mab for relapsed follicular lymphoma. Nat Rev Clin Oncol 2010;7:677–678.
- Jaime-Pérez JC, Rodríguez-Romo LN, González-Llano O, . Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 2009;144:794–795.
- Liu C-Y, Teng H-W, Lirng J-F, . Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma 2008;49:2018–2021.
- Rubenstein JL, Fridlyand J, Abrey L, . Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350–1356.
- Kitzmann AS, Pulido JS, Mohney BG, . Intraocular use of rituximab. Eye 2007;21:1524–1527.
- Paul T, Radny P, Kröber SM, . Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001;144:1239–1243.
- Peinert S, Kamel S, Seymour JF, . Intralesional rituximab for the treatmentof localised palatal relapse of follicular lymphoma. Leuk Lymphoma 2009;50:303–305.
- Yamamoto W, Tomita N, Watanabe R, . Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 2010;85:6–10.
- Swinnen LJ. Primary central nervous system lymphoma: recent progress, many remaining questions. Curr Opin Oncol 2009;21:393–396.
- Antonini G, Cox M, Montefusco E, . Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 2007;81:197–199.
- Rubenstein JL, Combs D, Rosenberg J, . Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466–468.
- Schulz H, Pels H, Schmidt-Wolf I, . Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004;89: 753–754.
- Singh AD, Peereboom DM. Intraocular rituximab. Eye 2007;21: 1453–1454.
- Law MF, Yip SF, Poon WL, . Intrapleural rituximab for the treatment of malignant pleural effusion due to B-cell lymphomas. Leuk Lympoma 2011;52:XXX–XXX.
- Schmidt H, Renner H, Linkesch W. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL. Haematologica 2004;89:ECR39.
- Ng T, Pagliuca A, Mufti GJ. Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. Ann Hematol 2002;81:405–406.
- Crysandt M, Neumann B, Das M, . Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol 2007;79:546–549.